Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches.

Objective: Human papillomavirus (HPV) is the main cause of cervical cancer, the 4 prominent cause of death in women globally. Previous vaccine development projects have led to several approved prophylactic vaccines available commercially, all of which are made using major capsid-based (L1). Administration of minor capsid protein (L2) gave rise to the second generation investigational prophylactic HPV vaccines, none of which are approved yet due to low immunogenicity provided by the L2 capsid protein.

Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations.

Unlabelled: The ongoing global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has prompted worldwide vaccine development. Several vaccines have been authorized by WHO, FDA, or MOH of different countries. However, issues such as need for cold chain, price, and most importantly access problems have limited vaccine usage in some nations especially developing countries.

Administration of COVID-19 vaccines in immunocompromised patients.

Since the beginning of vaccination programs against COVID-19 in different countries, several populations such as patients with specific immunological conditions have been considered as the priorities for immunization. In this regard, patients with autoimmune diseases or those receiving immunosuppressive agents and anti-cancer therapies, need special attention. However, no confirmed data is presently available regarding COVID-19 vaccines in these populations due to exclusion from the conducted clinical trials.

Interferon-inducer antivirals: Potential candidates to combat COVID-19.

Coronavirus disease 2019 (COVID-19) is an infective disease generated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the pandemic urgency and lack of an effective cure for this disease, drug repurposing could open the way for finding a solution. Lots of investigations are ongoing to test the compounds already identified as antivirals.

Using surrogate markers in primary electronic patient record systems to confirm or refute the diagnosis of diabetes.

Background: UK primary care records are computerised and these records are used for both research and quality improvement. However, there is disparity in the prevalence of diabetes found in epidemiological studies compared with that reported through the UK's national quality improvement scheme.

Objective: To investigate how non-diagnostic computer data could be used to identify, confirm or refute prevalent cases of people with diabetes.